Abstract:COVID-19 is a viral pandemic caused by SARS-CoV-2. Due to its highly contagious nature, millions of people are getting affected worldwide knocking down the delicate global socio-economic equilibrium. According to the World Health Organization, COVID-19 has affected over 186 million people with a mortality of around 4 million as of July 09, 2021. Currently, there are few therapeutic options available for COVID-19 control. The rapid mutations in SARS-CoV-2 genome and development of new virulent strains with increased infection and mortality among COVID-19 patients, there is a great need to discover more potential drugs for SARS-CoV-2 on a priority basis. One of the key viral enzymes responsible for the replication and maturation of SARS-CoV-2 is M-pro protein. In the current study, structure-based virtual screening was used to identify four potential ligands against SARS-CoV-2 M-pro from a set of 8,722 ASINEX library compounds. These four compounds were evaluated using ADME filter to check their ADME profile and druggability, and all the four compounds were found to be within the current pharmacological acceptable range. They were individually docked to SARS-CoV-2 M-pro protein to assess their molecular interactions. Further, molecular dynamics (MD) simulations was carried out on protein-ligand complex using Desmond at 100 ns to explore their binding conformational stability. Based on RMSD, RMSF and hydrogen bond interactions, it was found that the stability of protein-ligand complex was maintained throughout the entire 100 ns simulations for all the four compounds. Some of the key ligand amino acid residues participated in stabilizing the protein-ligand interactions includes GLN 189, SER 10, GLU 166, ASN 142 with PHE 66 and TRP 132 of SARS-CoV-2 M-pro. Further optimization of these compounds could lead to promising drug candidates for SARS-CoV-2 M-pro target.

Structural Biology of SARS-CoV-2 Mpro and Drug Discovery.

REVISITING THE SARS-COV-2 MAIN PROTEASE: A 2023 IN SILICO ODYSSEY IN SEARCH OF POTENTIAL INHIBITORS

Structure-based Virtual Screening, in Silico Docking, ADME Properties Prediction and Molecular Dynamics Studies for the Identification of Potential Inhibitors Against SARS-CoV-2 Mpro.

Structures of Two Coronavirus Main Proteases: Implications for Substrate Binding and Antiviral Drug Design.

Structural Basis of Potential Inhibitors Targeting SARS-CoV-2 Main Protease

Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors

Advances in the Search for SARS-CoV-2 Mpro and PLpro Inhibitors

Structural basis for replicase polyprotein cleavage and substrate specificity of main protease from SARS-CoV-2

Structural review of SARS-CoV-2 antiviral targets

Progress in Research on Inhibitors Targeting SARS-CoV-2 Main Protease (M pro )

Crystal Structure of SARS-CoV-2 Main Protease (mpro) Mutants in Complex with the Non-Covalent Inhibitor CCF0058981.

Targeting SARS-CoV-2 Proteases for COVID-19 Antiviral Development

Structure of Mpro from COVID-19 virus and discovery of its inhibitors

First structure–activity relationship analysis of SARS-CoV-2 virus main protease (Mpro) inhibitors: an endeavor on COVID-19 drug discovery

Discovery of 3-Oxo-1,2,3,4-tetrahydropyrido[1,2-a]pyrazin Derivatives As SARS-CoV-2 Main Protease Inhibitors Through Virtual Screening and Biological Evaluation.

Fragment-based Drug Discovery Strategy and its Application to the Design of SARS-CoV-2 Main Protease Inhibitor

Crystal structures of main protease (Mpro) mutants of SARS-CoV-2 variants bound to PF-07304814

Structural Basis of Main Proteases of Coronavirus Bound to Drug Candidate PF-07304814.

Potential Inhibitors for Targeting Mpro and Spike of SARS-CoV-2 Based on Sequence and Structural Pharmacology Analysis

The crystal structure of COVID 19 main protease in complex with an inhibitor 11a

Structure of M<sup>pro</sup>from COVID-19 virus and discovery of its inhibitors